Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal clinical trial assessing IDRX 42

Next Previous
Trial Profile

A pivotal clinical trial assessing IDRX 42

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDRX-42 (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms StrateGIST 3

Most Recent Events

  • 14 Nov 2024 According to IDRx media release, company aligned with the U.S. Food and Drug Administration (FDA) on trial design, dose, endpoints and statistical analysis for planned Phase 3 registrational study in second-line GIST.
  • 07 Aug 2024 According to IDRx media release, the company announced completion of an oversubscribed $120 million Series B Preferred Stock financing and proceeds will be used to fund the expected initiation of the first pivotal study for IDRX-42 in patients with second-line GIST.
  • 29 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top